WG Critical Care (WGCC), A Pharmasphere Company, Launches The First And Only Generic Ready-To-Use Esmolol Hydrochloride In Water For Injection

Esmolol will be available in two presentations—ready-to-use Esmolol HCl In Water for Injection 2500 mg/250mL and ready-to-use Esmolol HCl DOUBLE STRENGTH In Water for Injection 2000 mg/100 mL. Both presentations are available in single-dose, dual-port bags. WGCC's Esmolol bag and bag ports are free of natural rubber latex, PVC-free, DEHP-free and bar-coded at the unit of use. In order to enhance supply chain integrity, this product meets the next level of the Drug Supply Chain Security Act serialization requirements that went into effect November 27, 2017. According to IQVIA™ IMS Health data, sales of Brevibloc™ in the United States in 2017 were $101 million, an increase of $28 million from 2016.

"The WGCC ready-to-use Esmolol HCl in Water for Injection active ingredient, Esmolol, is the same as the innovator product, however uses WFI as the diluent rather than sodium chloride, eliminating the need to consider saline in salt-sensitive patients," stated Ronald Mannino RPh, Past President of the New Jersey Pharmacists Association and CEO of Pharmasphere, Inc.

"I'm excited to be able to introduce a generic, ready-to-use Esmolol HCl in Water for Injection to the US market. Esmolol is used in the ICU, surgery and the emergency room. The WGCC ready-to-use bag uses a proprietary sterilization process that results in a transparent bag when removed from the overwrap making it ideal for STAT or "need now" dosing," explained Joe Pizza, President of Pharmasphere, Inc.

About Esmolol Hydrochloride
Esmolol Hydrochloride is a beta₁-selective (cardioselective) adrenergic receptor-blocking agent. Esmolol hydrochloride is indicated for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent situations. Esmolol HCl is also indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period.

About WG Critical Care, A Pharmasphere Company
WG Critical Care, LLC is a subsidiary Pharmasphere, Inc. Pharmasphere and its affiliates bring over thirty-five years of experience in finished dose and API development and manufacturing, supplying nearly 40 million units of finished dose, sterile injectables annually since 2011. In 2012, WGCC began marketing directly to the US market with a focus on supplying conventional injectable products, as well as more convenient drug presentations. WGCC is headquartered in Paramus, New Jersey, and offers an extensive line of acute care hospital products. Please visit www.wgccrx.com for more information on the WGCC full line of essential injectable products. 

Brevibloc is a trademark of Baxter International Inc., or its subsidiaries.

SOURCE WG Critical Care, LLC

Related Links

http://www.wgccrx.com